Parkinson's disease (PD) is a common neurodegenerative movement disorder characterized by tremor, bradykinesia, postural instability and muscular rigidity. Neuropathologically, it is defined by cell loss in the substantia nigra associated with the presence of intraneuronal inclusions called Lewy bodies (LB) and processes engorged with proteinaceous material, the Lewy neurites. The recent identification of mutations in the a-synuclein gene in some familial forms of PD 3 ' 6 and the demonstration of accumulation of the protein in Lewy bodies and Lewy neurites 7 suggest that abnormal protein aggregation may cause the disease. In addition to asynuclein, LBs contain ubiquitin, proteasomal subunits 2 and ubiquitin C-terminal hydrolase-Ll, 5 pointing to a potential participation of the ubiquitin-proteasome degradation pathway in the onset of the disease. We confirmed this hypothesis by identifying a missense mutation in the ubiquitin C-terminal hydrolase LI (UCH-L1) gene in a German family with an autosomal dominant form of PD. 4 UCH-L1 is highly specific for neurons and cells of the diffuse neuroendocrine system, and represents 1% to 5% of the total brain protein extract. 8 Northern blot analysis reveals a 1.3-kb brain-specific transcript broadly represented in all areas of the brain tested, particularly in the substantia nigra (Fig. 1) . Enzymes belonging to the ubiquitin C-terminal hydrolases family can remove small amides and esters at the carboxyl terminus of ubiquitin and have been shown to hydrolyze peptides and small proteins similarly (reviewed in 9). They contribute to the pool of free monomeric ubiquitin molecules by hydrolysing the ubiquitin polymeric proprotein or ubiquitin-ribosomal fusion proteins during the maturation of the ribosome. 9 The Ile93Met mutation observed in 2 PD patients 4 causes a partial loss of catalytic activity of the UCH-L1 enzyme which could induce aberrations in the degradation pathway and lead to aggregation of proteins. To permit the rapid screening for mutations and assess the UCH-L1 role in PD, we have established specific amplification assays for all of its coding exons. Day et al. 1 have previously described 9 coding exons for the UCH-L1 gene. We have now determined the intron sequences flanking these 9 exons (Fig. 2 ) and have designed specific primers to amplify the gene exon sequences. PI derived artificial chromosome (PAC, Genome System, St. Louis, MO) and human genomic DNA were used as sequencing template. All boundaries were sequenced with the exception of those of exon 1 and 2 previously published (GenBank accession #X17377). Intron 6 was fully sequenced while the size of the remaining introns was estimated by PCR using primers from neighbouring exons. All resulting intronic/exonic sequences have been submited to GenBank (Accession #AF076269, AF060834, AF076270-AF076273, Table 1 ) and provide a minimum of 27 nucleotides after the splice junctions. As seen in Fig. 2 , splice donor and acceptor sites fit the consensus sequences. The short nucleotide inversion at the 5' end of the published cDNA sequence reported by Day et al. was confirmed by our results. Table 1 provides 7 sets of intronic oligonucleotides that can be used to amplify and sequence all the coding exons and the associated splice donor and acceptor sites. The DNA sequence between exons 1 and 3 has a GC content greater than 60% and can be amplified in the presence of 5% formamide and 10% glycerol. Exons 4, 7 and 8 are amplified using a "touchdown" PCR where the annealing temperature of the reaction is decreased by 1°C every cycle from 67° C to 60° C, at which temperature 25 cycles are then carried out. Exons 5, 6 and 9 are amplified using standard PCR conditions.
The description of the UCH-L1 intron-exon structure and the development of specific amplification assays for all of its coding exons should permit the search for mutations in patients with Parkinson's disease. Further mutation analysis should facilitate the understanding of the role of UCH-L1 in the etiology of other neurodegenerative diseases associated with protein deposition. Indianapolis, IN) . Hybridization was performed at 42°C in 5x SSC, 5x Denhardt's solution, 1% SDS and 20% formamide in the presence of 100 mg/ml of salmon sperm DNA. Filters were washed in 2x SSC, 1% SDS at room temperature before being exposed for autoradiography. Numbers on the left indicate RNA size markers in kb. mi. 105bp  exon2  12bp  intron2  463bp  exon3 129bp  intron3  2700bp  exon4 151bp  intron4  950bp  exon5 
